Tildrakizumab is under clinical development by Sun Pharmaceutical Industries and currently in Phase III for Psoriatic Arthritis. According to GlobalData, Phase III drugs for Psoriatic Arthritis have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tildrakizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tildrakizumab overview
Tildrakizumab (Ilumya, Ilumetri) is a monoclonal antibody, acts as an immunosuppressant agent. It is formulated as solution for subcutaneous route of administration. Tildrakizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Tildrakizumab is under development for the treatment of psoriatic arthritis and plaque psoriasis. It was also under development for ankylosing spondylitis and axial spondyloarthritis.
Sun Pharmaceutical Industries overview
Sun Pharmaceutical Industries (Sun Pharma) is a specialty pharmaceutical company that offers a wide range of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s portfolio includes products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic and ophthalmologic diseases and disorders, and heart diseases. The company carries out product development, process chemistry, and manufacture of complex formulations, active pharmaceutical ingredients (APIs) and over-the-counter products. It offers drugs in various dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company has manufacturing facilities in North America, Latin America, EMEA and Asia Pacific. Sun Pharma is headquartered in Mumbai, Maharashtra, India.
For a complete picture of Tildrakizumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
